Considerations On Ex Vivo Conversion Of Prodrugs During Bioanalysis Bioanalysis 2020

Summary

Xiaohan Cai, CDER Office of Study Integrity and Surveillance Session (OSIS), discusses Arindam Dasgupta, Deputy Director, Division of New Drug Study Integrity, Office of Translational Sciences, shares background ... Zhen Zhang, CDER Office of Generic Drugs, explains the regulatory requirements for stability and how to identify and resolve ... Sriram Subramaniam, CDER Office of Clinical Pharmacology, discusses Director of the Office of Translational Sciences (OTS) ShaAvhrée Buckman-Garner, MD, PhD, FAAP, opened the meeting ... Salaheldin S. Hamed, CDER Office of Clinical Pharmacology, provides an introduction to biosimilars to include submission ... Presenters Patrick Faustino, Jinhui Zhang, and Diaa Shakleya respond to audience questions. FDA CDER's Small Business and ... Jinhui Zhang, CDER Office of Pharmaceutical Quality, discusses the Biologics Price Competition and Innovation Act (BPCI) Act ... Diaa Shakleya, CDER Office of Pharmaceutical Quality (OPQ), discusses Tian Ma, CDER Office of Generic Drugs, summarize common reasons/codes of study sample reanalysis Subject:Pharmaceutical Science Paper:BIO PHARMACEUTICS AND PHARMACOKINETICS. Tannaz Ramezanli from the Office of Generic Drugs discusses recent pre-clinical and clinical study results from GDUFA-funded ... Patrick Faustino, CDER Office of Pharmaceutical Quality (OPQ), provides context for